Alzheimer Disease.
Journal
Continuum (Minneapolis, Minn.)
ISSN: 1538-6899
Titre abrégé: Continuum (Minneap Minn)
Pays: United States
ID NLM: 9509333
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
entrez:
9
6
2022
pubmed:
10
6
2022
medline:
11
6
2022
Statut:
ppublish
Résumé
Alzheimer disease (AD) is the most common cause of dementia in adults (mid to late life), highlighting the importance of understanding the risk factors, clinical manifestations, and recent developments in diagnostic testing and therapeutics. Advances in fluid (CSF and blood-based) and imaging biomarkers are allowing for a more precise and earlier diagnosis of AD (relative to non-AD dementias) across the disease spectrum and in patients with atypical clinical features. Specifically, tau- and amyloid-related AD pathologic changes can now be measured by CSF, plasma, and positron emission tomography (PET) with good precision. Additionally, a better understanding of risk factors for AD has highlighted the need for clinicians to address comorbidities to maximize prevention of cognitive decline in those at risk or to slow decline in patients who are symptomatic. Recent clinical trials of amyloid-lowering drugs have provided not only some optimism that amyloid reduction or prevention may be beneficial but also a recognition that addressing additional targets will be necessary for significant disease modification. Recent developments in fluid and imaging biomarkers have led to the improved understanding of AD as a chronic condition with a protracted presymptomatic phase followed by the clinical stage traditionally recognized by neurologists. As clinical trials of potential disease-modifying therapies continue, important developments in the understanding of the disease will improve clinical care now and lead to more effective therapies in the near future.
Identifiants
pubmed: 35678397
doi: 10.1212/CON.0000000000001131
pii: 00132979-202206000-00004
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
tau Proteins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
648-675Informations de copyright
Copyright © 2022 American Academy of Neurology.
Références
Jack CR Jr, Wiste HJ, Botha H, et al. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. Brain 2019;142(10):3230–3242. doi:10.1093/brain/awz268
doi: 10.1093/brain/awz268
2021 Alzheimer’s disease facts and figures. Alzheimers Dement 2;17(3):327–406. doi:10.1002/alz.12328
doi: 10.1002/alz.12328
Power MC, Bennett EE, Turner RW, et al. Trends in relative incidence and prevalence of dementia across non-Hispanic Black and White individuals in the United States, 2000-2016. JAMA Neurol 2021;78(3):275–284. doi:10.1001/jamaneurol.2020.4471
doi: 10.1001/jamaneurol.2020.4471
Satizabal CL, Beiser AS, Chouraki V, et al. Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med 2016;374(6):523–532. doi:10.1056/NEJMoa1504327
doi: 10.1056/NEJMoa1504327
Downer B, Garcia MA, Raji M, Markides KS. Cohort differences in cognitive impairment and cognitive decline among Mexican-Americans aged 75 years or older. Am J Epidemiol 2019;188(1):119–129. doi:10.1093/aje/kwy196
doi: 10.1093/aje/kwy196
Xiong C, Luo J, Coble D, et al. Complex interactions underlie racial disparity in the risk of developing Alzheimer’s disease dementia. Alzheimers Dement 2020;16(4):589–597. doi:10.1002/alz.12060
doi: 10.1002/alz.12060
Garrett SL, McDaniel D, Obideen M, et al. Racial disparity in cerebrospinal fluid amyloid and tau biomarkers and associated cutoffs for mild cognitive impairment. JAMA Netw Open 2019;2(12):e1917363. doi:10.1001/jamanetworkopen.2019.17363
doi: 10.1001/jamanetworkopen.2019.17363
Morris JC, Schindler SE, McCue LM, et al. Assessment of racial disparities in biomarkers for Alzheimer disease. JAMA Neurol 2019;76(3):264–273. doi:10.1001/jamaneurol.2018.4249
doi: 10.1001/jamaneurol.2018.4249
Schindler SE, Cruchaga C, Joseph A, et al. African Americans have differences in CSF soluble TREM2 and associated genetic variants. Neurol Genet 2021;7(2):e571. Accessed April 4, 2022. ng.neurology.org/content/7/2/e571
Balls-Berry JE, Babulal GM. Health disparities in dementia. Continuum (Minneap Minn) 2022;28(3, Dementia):872–884.
Boyle PA, Yu L, Wilson RS, et al. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol 2018;83(1):74–83. doi:10.1002/ana.25123
doi: 10.1002/ana.25123
Boyle PA, Yang J, Yu L, et al. Varied effects of age-related neuropathologies on the trajectory of late life cognitive decline. Brain 2017;140(3):804–812. doi:10.1093/brain/aww341
doi: 10.1093/brain/aww341
Brenowitz WD, Keene CD, Hawes SE, et al. Alzheimer’s disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples. Neurobiol Aging 2017;53:83–92. doi:10.1016/j.neurobiolaging.2017.01.017
doi: 10.1016/j.neurobiolaging.2017.01.017
Townley RA, Graff-Radford J, Mantyh WG, et al. Progressive dysexecutive syndrome due to Alzheimer’s disease: a description of 55 cases and comparison to other phenotypes. Brain Commun 2020;2(1):fcaa068. doi:10.1093/braincomms/fcaa068
doi: 10.1093/braincomms/fcaa068
Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 2015;313(19):1939–1949. doi:10.1001/jama.2015.4669
doi: 10.1001/jama.2015.4669
Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015;313(19):1924–1938. doi:10.1001/jama.2015.4668
doi: 10.1001/jama.2015.4668
Salloway S, Farlow M, McDade E, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease. Nat Med 2021;27(7):1187–1196. doi:10.1038/s41591-021-01369-8
doi: 10.1038/s41591-021-01369-8
Reiman EM, Langbaum JBS, Fleisher AS, et al. Alzheimer’s prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011;26(suppl 3):321–329. doi:10.3233/JAD-2011-0059
doi: 10.3233/JAD-2011-0059
Insel PS, Donohue MC, Sperling R, et al. The A4 study: β-amyloid and cognition in 4432 cognitively unimpaired adults. Ann Clin Transl Neurol 2020;7(5):776–785. doi:10.1002/acn3.51048
doi: 10.1002/acn3.51048
Jack CR, Wiste HJ, Weigand SD, et al. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol 2014;13(10):997–1005. doi:10.1016/S1474-4422(14)70194-2
doi: 10.1016/S1474-4422(14)70194-2
Karch CM, Goate AM. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 2015;77(1):43–51. doi:10.1016/j.biopsych.2014.05.006
doi: 10.1016/j.biopsych.2014.05.006
Li Z, Shue F, Zhao N, et al. APOE2: protective mechanism and therapeutic implications for Alzheimer's disease. Mol Neurodegener 2020;4;15(1):63. doi:10.1186/s13024-020-00413-4
doi: 10.1186/s13024-020-00413-4
Xiong M, Jiang H, Serrano JR, et al. APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Sci Transl Med 2021;13(581):eabd7522. doi:10.1126/scitranslmed.abd7522
doi: 10.1126/scitranslmed.abd7522
Desikan RS, Fan CC, Wang Y, et al. Genetic assessment of age-associated Alzheimer disease risk: development and validation of a polygenic hazard score. PLoS Med 2017;14(3):e1002258. doi:10.1371/journal.pmed.1002258
doi: 10.1371/journal.pmed.1002258
Yu J-T, Xu W, Tan C-C, et al. Evidence-based prevention of Alzheimer’s disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. J Neurol Neurosurg Psychiatry 2020;91(11):1201–1209. doi:10.1136/jnnp-2019-321913
doi: 10.1136/jnnp-2019-321913
Hörder H, Johansson L, Guo X, et al. Midlife cardiovascular fitness and dementia: a 44-year longitudinal population study in women. Neurology 2018;90(15):e1298–e1305. doi:10.1212/WNL.0000000000005290
doi: 10.1212/WNL.0000000000005290
Ma F, Wu T, Zhao J, et al. Folic acid supplementation improves cognitive function by reducing the levels of peripheral inflammatory cytokines in elderly Chinese subjects with MCI. Sci Rep 2016;6:37486. doi:10.1038/srep37486
doi: 10.1038/srep37486
Ju Y-ES, Ooms SJ, Sutphen C, et al. Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels. Brain 2017;140(8):2104–2111. doi:10.1093/brain/awx148
doi: 10.1093/brain/awx148
Musiek ES, Bhimasani M, Zangrilli MA, et al. Circadian rest-activity pattern changes in aging and preclinical Alzheimer disease. JAMA Neurol 2018;75(5):582–590. doi:10.1001/jamaneurol.2017.4719
doi: 10.1001/jamaneurol.2017.4719
Bubu OM, Pirraglia E, Andrade AG, et al. Obstructive sleep apnea and longitudinal Alzheimer’s disease biomarker changes. Sleep 2019;42(6):zsz048. doi:10.1093/sleep/zsz048
doi: 10.1093/sleep/zsz048
Ju Y-ES, Zangrilli MA, Finn MB, et al. Obstructive sleep apnea treatment, slow wave activity, and amyloid-β. Ann Neurol 2019;85(2):291–295. doi:10.1002/ana.25408
doi: 10.1002/ana.25408
Kwok MK, Schooling CM. Herpes simplex virus and Alzheimer’s disease: a Mendelian randomization study. Neurobiol Aging 2021;99:101.e11–101.e13. doi:10.1016/j.neurobiolaging.2020.09.025
doi: 10.1016/j.neurobiolaging.2020.09.025
Tzeng N-S, Chung C-H, Lin F-H, et al. Anti-herpetic medications and reduced risk of dementia in patients with herpes simplex virus infections—a nationwide, population-based cohort study in Taiwan. Neurotherapeutics 2018;15(2):417–429. doi:10.1007/s13311-018-0611-x
doi: 10.1007/s13311-018-0611-x
Lopatko Lindman K, Hemmingsson E-S, Weidung B, et al. Herpesvirus infections, antiviral treatment, and the risk of dementia—a registry-based cohort study in Sweden. Alzheimers Dement (N Y) 2021;7(1):e12119. doi:10.1002/trc2.12119
doi: 10.1002/trc2.12119
Devanand DP, Andrews H, Kreisl WC, et al. Antiviral therapy: Valacyclovir Treatment of Alzheimer’s Disease (VALAD) trial: protocol for a randomised, double-blind, placebo-controlled, treatment trial. BMJ Open 2020;10(2):e032112. doi:10.1136/bmjopen-2019-032112
doi: 10.1136/bmjopen-2019-032112
Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56(9):1143–1153. doi:10.1212/wnl.56.9.1143
doi: 10.1212/wnl.56.9.1143
Schindler SE. Fluid biomarkers in dementia diagnosis. Continuum (Minneap Minn) 2022;28(3, Dementia):822–833.
Raji CA, Benzinger TLS. The value of neuroimaging in dementia diagnosis. Continuum (Minneap Minn) 2022;28(3, Dementia):800–821.
Brodaty H, Seeher K, Gibson L. Dementia time to death: a systematic literature review on survival time and years of life lost in people with dementia. Int Psychogeriatr 2012;24(7):1034–1045. doi:10.1017/S1041610211002924
doi: 10.1017/S1041610211002924
Todd S, Barr S, Roberts M, Passmore AP. Survival in dementia and predictors of mortality: a review. Int J Geriatr Psychiatry 2013;28(11):1109–1124. doi:10.1002/gps.3946
doi: 10.1002/gps.3946
Mesulam MM. Large-scale neurocognitive networks and distributed processing for attention, language, and memory. Ann Neurol 1990;28(5):597–613. doi:10.1002/ana.410280502
doi: 10.1002/ana.410280502
Leng K, Li E, Eser R, et al. Molecular characterization of selectively vulnerable neurons in Alzheimer’s disease. Nat Neurosci 2021;24(2):276–287. doi:10.1038/s41593-020-00764-7
doi: 10.1038/s41593-020-00764-7
Seeley WW, Crawford RK, Zhou J, et al. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009;62(1):42–52. doi:10.1016/j.neuron.2009.03.024
doi: 10.1016/j.neuron.2009.03.024
Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018;90(3):126–135. doi:10.1212/WNL.0000000000004826
doi: 10.1212/WNL.0000000000004826
Jack CR Jr, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease. Brain 2010;133(11):3336–3348. doi:10.1093/brain/awq277
doi: 10.1093/brain/awq277
Vos SJB, Verhey F, Frölich L, et al. Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage. Brain 2015;138(pt 5):1327–1338. doi:10.1093/brain/awv029
doi: 10.1093/brain/awv029
Lombardi G, Crescioli G, Cavedo E, et al. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer’s disease in people with mild cognitive impairment. Cochrane Database Syst Rev 2020;3(3):CD009628. doi:10.1002/14651858.CD009628.pub2
doi: 10.1002/14651858.CD009628.pub2
Dreyfus DM, Roe CM, Morris JC. Autobiographical memory task in assessing dementia. Arch Neurol 2010;67(7):862–826. doi:10.1001/archneurol.2010.145
doi: 10.1001/archneurol.2010.145
Breton A, Casey D, Arnaoutoglou NA. Cognitive tests for the detection of mild cognitive impairment (MCI), the prodromal stage of dementia: meta-analysis of diagnostic accuracy studies. Int J Geriatr Psychiatry 2019;34(2):233–242. doi:10.1002/gps.5016
doi: 10.1002/gps.5016
Ismail Z, Gatchel J, Bateman DR, et al. Affective and emotional dysregulation as pre-dementia risk markers: exploring the mild behavioral impairment symptoms of depression, anxiety, irritability, and euphoria. Int Psychogeriatr 2018;30(2):185–196. doi:10.1017/S1041610217001880
doi: 10.1017/S1041610217001880
Mallo SC, Ismail Z, Pereiro AX, et al. Assessing mild behavioral impairment with the mild behavioral impairment—checklist in people with mild cognitive impairment. J Alzheimers Dis 2018;66(1):83–95. doi:10.3233/JAD-180131
doi: 10.3233/JAD-180131
Demichele-Sweet MAA, Lopez OL, Sweet RA. Psychosis in Alzheimer’s disease in the national Alzheimer’s disease coordinating center uniform data set: clinical correlates and association with apolipoprotein e. Int J Alzheimers Dis 2011;2011:926597. doi:10.4061/2011/926597
doi: 10.4061/2011/926597
Scarmeas N, Brandt J, Albert M, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol 2005;62(10):1601–1608. doi:10.1001/archneur.62.10.1601
doi: 10.1001/archneur.62.10.1601
Scarmeas N, Hadjigeorgiou GM, Papadimitriou A, et al. Motor signs during the course of Alzheimer disease. Neurology 2004;63(6):975–982. doi:10.1212/01.wnl.0000138440.39918.0c
doi: 10.1212/01.wnl.0000138440.39918.0c
Scarmeas N, Honig LS, Choi H, et al. Seizures in Alzheimer disease: who, when, and how common?Arch Neurol 2009;66(8):992–997. doi:10.1001/archneurol.2009.130
doi: 10.1001/archneurol.2009.130
Vossel KA, Ranasinghe KG, et al. Incidence and impact of subclinical epileptiform activity in Alzheimer’s disease. Ann Neurol 2016;80(6):858–870. doi:10.1002/ana.24794
doi: 10.1002/ana.24794
Beagle AJ, Darwish SM, Ranasinghe KG, et al. Relative incidence of seizures and myoclonus in Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal dementia. J Alzheimers Dis 2017;60(1):211–223. doi:10.3233/JAD-170031
doi: 10.3233/JAD-170031
Hiller AJ, Ishii M. Disorders of body weight, sleep and circadian rhythm as manifestations of hypothalamic dysfunction in Alzheimer’s disease. Front Cell Neurosci 2018;12:471. doi:10.3389/fncel.2018.00471
doi: 10.3389/fncel.2018.00471
Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004;62(2):181–187. doi:10.1212/wnl.62.2.181
doi: 10.1212/wnl.62.2.181
Goldman JG, Holden SK. Cognitive syndromes associated with movement disorders. Continuum (Minneap Minn) 2022;28(3, Dementia):726–749.
Polsinelli AJ, Apostolova LG. Atypical Alzheimer disease variants. Continuum (Minneap Minn) 2022;28(3, Dementia):676–701.
Barnes J, Dickerson BC, Frost C, et al. Alzheimer’s disease first symptoms are age dependent: evidence from the NACC dataset. Alzheimers Dement 2015;11(11):1349–1357. doi:10.1016/j.jalz.2014.12.007
doi: 10.1016/j.jalz.2014.12.007
Murray ME, Graff-Radford NR, Ross OA, et al. Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 2011;10(9):785–796. doi:10.1016/S1474-4422(11)70156-9
doi: 10.1016/S1474-4422(11)70156-9
Lacour M, Quenez O, Rovelet-Lecrux A, et al. Causative mutations and genetic risk factors in sporadic early onset Alzheimer’s disease before 51 years. J Alzheimers Dis 2019;71(1):227–243. doi:10.3233/JAD-190193
doi: 10.3233/JAD-190193
Fitzpatrick AWP, Falcon B, He S, et al. Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature 2017;547(7662):185–190. doi:10.1038/nature23002
doi: 10.1038/nature23002
Falcon B, Zhang W, Murzin AG, et al. Structures of filaments from Pick’s disease reveal a novel tau protein fold. Nature 2018;561(7721):137–140. doi:10.1038/s41586-018-0454-y
doi: 10.1038/s41586-018-0454-y
Qiang W, Yau W-M, et al. Structural variation in amyloid-β fibrils from Alzheimer’s disease clinical subtypes. Nature 2017;541(7636):217–221. doi:10.1038/nature20814
doi: 10.1038/nature20814
Dujardin S, Commins C, Lathuiliere A, et al. Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease. Nat Med 2020;26(8):1256–1263. doi:10.1038/s41591-020-0938-9
doi: 10.1038/s41591-020-0938-9
Barthélemy NR, Mallipeddi N, Moiseyev P, et al. Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer’s disease. Front Aging Neurosci 2019;11:121. doi:10.3389/fnagi.2019.00121
doi: 10.3389/fnagi.2019.00121
Barthélemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. J Exp Med 2020;217(11):e20200861. doi:10.1084/jem.20200861
doi: 10.1084/jem.20200861
Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 2020;324(8):772–781. doi:10.1001/jama.2020.12134
doi: 10.1001/jama.2020.12134
Chhatwal JP, Schultz AP, Dang Y, et al. Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals. Nat Commun 2020;11(1):6024. doi:10.1038/s41467-020-19543-w
doi: 10.1038/s41467-020-19543-w
Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018;14(4):535–562. doi:10.1016/j.jalz.2018.02.018
doi: 10.1016/j.jalz.2018.02.018
Vos SJB, Xiong C, Visser PJ, et al. Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013;12(10):957–965. doi:10.1016/S1474-4422(13)70194-7
doi: 10.1016/S1474-4422(13)70194-7
Petersen RC, Wiste HJ, Weigand SD, et al. NIA-AA Alzheimer’s Disease Framework: clinical characterization of stages. Ann Neurol 2021;89(6):1145–1156. doi:10.1002/ana.26071
doi: 10.1002/ana.26071
Ossenkoppele R, Schonhaut DR, Schöll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain 2016;139(5):1551–1567. doi:10.1093/brain/aww027
doi: 10.1093/brain/aww027
Blennow K, Zetterberg H. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med 2018;284(6):643–663. doi:10.1111/joim.12816
doi: 10.1111/joim.12816
Ashton NJ, Leuzy A, Karikari TK, et al. The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. Eur J Nucl Med Mol Imaging 2021;48(7):2140–2156. doi:10.1007/s00259-021-05253-y
doi: 10.1007/s00259-021-05253-y
West T, Kirmess KM, Meyer MR, et al. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Mol Neurodegener 2021;16(1):30. doi:10.1186/s13024-021-00451-6
doi: 10.1186/s13024-021-00451-6
Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 2019;93(17):e1647–e1659. doi:10.1212/WNL.0000000000008081
doi: 10.1212/WNL.0000000000008081
Gonzales MM, Short MI, Satizabal CL, et al. Blood biomarkers for dementia in Hispanic and non-Hispanic White adults. Alzheimers Dement (N Y) 2021;7(1):e12164. doi:10.1002/trc2.12164
doi: 10.1002/trc2.12164
Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2016;537(7618):50–56. doi:10.1038/nature19323
doi: 10.1038/nature19323
Dunn B, Stein P, Cavazzoni P. Approval of aducanumab for Alzheimer disease—the FDA’s perspective. JAMA Intern Med 2021;181(10):1276–1278. doi:10.1001/jamainternmed.2021.4607
doi: 10.1001/jamainternmed.2021.4607
Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer’s disease. N Engl J Med 2021;384(18):1691–1704. doi:10.1056/NEJMoa2100708
doi: 10.1056/NEJMoa2100708
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43(11):2412–2414. doi:10.1212/wnl.43.11.2412-a
doi: 10.1212/wnl.43.11.2412-a
Cummings J, Aisen P, Apostolova LG, et al. Aducanumab: appropriate use recommendations. J Prev Alzheimers Dis 2021;8(4):398–410. doi:10.14283/jpad.2021.41
doi: 10.14283/jpad.2021.41
McDade E, Libre-Guerra JJ, Holtzman DM, et al. The informed road map to prevention of Alzheimer disease: a call to arms. Mol Neurodegener 2021;16(1):49. doi:10.1186/s13024-021-00467-y
doi: 10.1186/s13024-021-00467-y
Cummings J, Lee G, Ritter A, et al. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement (N Y) 2019;5:272–293. doi:10.1016/j.trci.2019.05.008
doi: 10.1016/j.trci.2019.05.008
Park-Wyllie LY, Mamdani MM, Li P, et al. Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study. PLoS Med 2009;6(9):e1000157. doi:0.1371/journal.pmed.1000157
doi: 0.1371/journal.pmed.1000157
Fleet JL, McArthur E, Patel A, et al. Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study. CMAJ 2019;16;191(37):E1018–E1024. doi:10.1503/cmaj.190337
doi: 10.1503/cmaj.190337
Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clin Ther 2010;32(7):1234–1251. doi:10.1016/j.clinthera.2010.06.019
doi: 10.1016/j.clinthera.2010.06.019
Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2018;6(6):CD001190. doi:10.1002/14651858
doi: 10.1002/14651858
Cheng Y-C, Huang Y-C, Liu H-C. Effect of apolipoprotein E ɛ4 carrier status on cognitive response to acetylcholinesterase inhibitors in patients with Alzheimer’s disease: a systematic review and meta-analysis. Dement Geriatr Cogn Disord 2018;45(5-6):335–352. doi:10.1159/000490175
doi: 10.1159/000490175
Han J-Y, Besser LM, Xiong C, et al. Cholinesterase inhibitors may not benefit mild cognitive impairment and mild Alzheimer disease dementia. Alzheimer Dis Assoc Disord 2019;33(2):87–94. doi:10.1097/WAD.0000000000000291
doi: 10.1097/WAD.0000000000000291
Reynolds CF 3rd, Butters MA, Lopez O, et al. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry 2011;68(1):51–60. doi:10.1001/archgenpsychiatry.2010.184
doi: 10.1001/archgenpsychiatry.2010.184
Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA Cooperative Randomized Trial. JAMA 2014;311(1):33–44. doi:10.1001/jama.2013.282834
doi: 10.1001/jama.2013.282834
Hellmuth J, Rabinovici GD, Miller BL. The rise of pseudomedicine for dementia and brain health. JAMA 2019;321(6):543–544. doi:10.1001/jama.2018.21560
doi: 10.1001/jama.2018.21560
Stoehr GP, Jacobsen E, Jia Y, et al. Trends in the use of medications and supplements to treat or prevent dementia: a population-based study. Alzheimer Dis Assoc Disord 2020;34(2):148–155. doi:10.1097/WAD.0000000000000357
doi: 10.1097/WAD.0000000000000357
Scarmeas N, Anastasiou CA, Yannakoulia M. Nutrition and prevention of cognitive impairment. Lancet Neurol 2018;17(11):1006–1015. doi:10.1016/S1474-4422(18)30338-7
doi: 10.1016/S1474-4422(18)30338-7
Ballarini T, Melo van Lent D, Brunner J, et al. Mediterranean diet, Alzheimer disease biomarkers and brain atrophy in old age. Neurology 2021;96(24):e2920–e2932. doi:10.1212/WNL.0000000000012067
doi: 10.1212/WNL.0000000000012067
Ballard C, Kales HC, Lyketsos C, et al. Psychosis in Alzheimer’s disease. Curr Neurol Neurosci Rep 2020;20(12):57. doi:10.1007/s11910-020-01074-y
doi: 10.1007/s11910-020-01074-y
Ballard C, O’Brien J, Coope B, et al. A prospective study of psychotic symptoms in dementia sufferers: psychosis in dementia. Int Psychogeriatr 1997;9(1):57–64. doi:10.1017/s1041610297004201
doi: 10.1017/s1041610297004201
Kales HC, Lyketsos CG, Miller EM, Ballard C. Management of behavioral and psychological symptoms in people with Alzheimer’s disease: an international Delphi consensus. Int Psychogeriatr 2019;31(1):83–90. doi:10.1017/S1041610218000534
doi: 10.1017/S1041610218000534
Cummings JL, McRae T, Zhang R. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry 2006;14(7):605–612. doi:10.1097/01.JGP.0000221293.91312.d3
doi: 10.1097/01.JGP.0000221293.91312.d3
Leonpacher AK, Peters ME, Drye LT, et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer’s dementia: evidence from the CitAD Study. Am J Psychiatry 2016;173(5):473–480. doi:10.1176/appi.ajp.2016.15020248
doi: 10.1176/appi.ajp.2016.15020248
Mintzer JE, Tune LE, Breder CD, et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry 2007;15(11):918–931. doi:10.1097/JGP.0b013e3181557b47
doi: 10.1097/JGP.0b013e3181557b47